Department of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, 410008, China.
Signal Transduct Target Ther. 2021 Nov 26;6(1):408. doi: 10.1038/s41392-021-00787-x.
Epstein-Barr virus (EBV) and human papillomavirus (HPV) infection is the risk factors for nasopharyngeal carcinoma and cervical carcinoma, respectively. However, clinical analyses demonstrate that EBV or HPV is associated with improved response of patients, although underlying mechanism remains unclear. Here, we reported that the oncoproteins of DNA viruses, such as LMP1 of EBV and E7 of HPV, inhibit PERK activity in cancer cells via the interaction of the viral oncoproteins with PERK through a conserved motif. Inhibition of PERK led to increased level of reactive oxygen species (ROS) that promoted tumor and enhanced the efficacy of chemotherapy in vivo. Consistently, disruption of viral oncoprotein-PERK interactions attenuated tumor growth and chemotherapy in both cancer cells and tumor-bearing mouse models. Our findings uncovered a paradoxical effect of DNA tumor virus oncoproteins on tumors and highlighted that targeting PERK might be an attractive strategy for the treatment of NPC and cervical carcinoma.
EBV 病毒和 HPV 病毒分别是鼻咽癌和宫颈癌的风险因素。然而,临床分析表明,尽管潜在机制尚不清楚,但 EBV 或 HPV 与患者的更好反应有关。在这里,我们报道了 DNA 病毒的致癌蛋白,如 EBV 的 LMP1 和 HPV 的 E7,通过病毒致癌蛋白与 PERK 的相互作用,通过保守基序抑制癌细胞中的 PERK 活性。PERK 的抑制导致活性氧(ROS)水平增加,从而促进肿瘤生长,并增强体内化疗的疗效。一致地,破坏病毒致癌蛋白-PERK 相互作用可减弱癌细胞和荷瘤小鼠模型中的肿瘤生长和化疗作用。我们的研究结果揭示了 DNA 肿瘤病毒致癌蛋白对肿瘤的矛盾作用,并强调靶向 PERK 可能是治疗 NPC 和宫颈癌的一种有吸引力的策略。